Heikamp Lab in the News

Revumenib was recently FDA approved for children and adults with KMT2A-rearranged leukemia: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation

We are proud of the preclinical and clinical work that was done at Dana-Farber to support the development of this first-in-class drug for leukemia.

Dr. Heikamp was recently named as the recipient of the Charles H. Hood Foundation Child Health Research Award. Read more about the Hood Foundation: https://charleshoodfoundation.org/

As a recipient of the Hyundai Hope on Wheels (HHOW) Young Investigator Award, Dr. Heikamp represented Dana-Farber at a check presentation ceremony at Fenway Park, home of the Boston Red Sox. Joined by Hyundai Dealership owners from across New England who have worked to raise funds that support pediatric cancer research, Dr. Heikamp was presented with a check that represented cumulative funds raised by HHOW awarded to Dana-Farber. The ceremony took place at the 2024 Fenway Pacesetter Event, which recognized top fundraising teams for the annual Jimmy Fund Walk.